Related Experiment Video
Updated: Jun 26, 2026

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
Published on: August 6, 2013
Pharmacotherapy for tobacco dependence
Reginald V Fant1, August R Buchhalter, Albert C Buchman
1Pinney Associates, Bethesda, MD 20814, USA. rfant@pinneyassociates.com
Pharmacotherapy effectively treats tobacco dependence and withdrawal, aiding sustained abstinence. Approved medications like nicotine replacement therapy (NRT), bupropion, and varenicline are reviewed for efficacy and safety.
Area of Science:
- Pharmacology
- Addiction Medicine
- Pharmacotherapy
Background:
- Tobacco dependence is a significant public health issue.
- Pharmacotherapy is a cornerstone of smoking cessation treatment.
- Existing medications include NRT, bupropion, and varenicline.
Purpose of the Study:
- To review the pharmacological basis of approved smoking cessation medications.
- To discuss factors influencing medication efficacy, safety, and abuse liability.
- To explore future directions in pharmacotherapy development for tobacco dependence.
Main Methods:
- Literature review of pharmacological principles and clinical data.
- Analysis of approved smoking cessation agents.
- Discussion of drug properties and their impact on treatment outcomes.
Main Results:
- Approved pharmacotherapies (NRT, bupropion, varenicline) offer effective treatment options.
- Medication properties influence efficacy, safety, and abuse potential.
- Pharmacological understanding can guide improvement of current and development of novel cessation aids.
Conclusions:
- Pharmacotherapy plays a vital role in achieving and maintaining tobacco abstinence.
- Further research into pharmacological mechanisms can optimize smoking cessation treatments.
- Targeted drug development holds promise for enhanced tobacco dependence management.
Related Concept Videos
Drug Dependence
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
CNS Depressants: Alcohol and Nicotine
Drug Therapy
Antianxiety Medications
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Pharmaceutical Poisoning: Treatment Strategies
